Mainz Biomed’s (MYNZ) “Sell (E)” Rating Reiterated at Weiss Ratings

Weiss Ratings restated their sell (e) rating on shares of Mainz Biomed (NASDAQ:MYNZ) in a report released on Tuesday,Weiss Ratings reports.

Mainz Biomed Price Performance

Shares of MYNZ stock opened at $1.41 on Tuesday. The firm has a market cap of $7.63 million, a P/E ratio of -0.02 and a beta of 0.25. The company has a debt-to-equity ratio of 0.44, a current ratio of 0.52 and a quick ratio of 0.43. Mainz Biomed has a 1-year low of $1.28 and a 1-year high of $14.39. The firm has a fifty day moving average of $1.63 and a two-hundred day moving average of $2.04.

Hedge Funds Weigh In On Mainz Biomed

An institutional investor recently raised its position in Mainz Biomed stock. Armistice Capital LLC lifted its holdings in Mainz Biomed NV (NASDAQ:MYNZ) by 45.0% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 285,000 shares of the company’s stock after purchasing an additional 88,400 shares during the period. Armistice Capital LLC owned about 6.23% of Mainz Biomed worth $402,000 at the end of the most recent reporting period.

Mainz Biomed Company Profile

Mainz Biomed N.V. develops and sells in-vitro diagnostic tests for the early detection of cancer in the United States. The company offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. It also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer.